NYSE · PRGO
Healthcare · Drug Manufacturers - Specialty & Generic
$15.78
Down-$0.12 (-0.75%)
Updated Oct 31, 2026, 4:28 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PRGO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
PRGO closed at $15.78 after 21 trading sessions, up 10.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $16.07 | $16.14 | $15.42 | $15.78 | 3.35M |
| Oct 29, 2026 | $16.05 | $16.27 | $15.715 | $15.90 | 2.29M |
| Oct 28, 2026 | $15.96 | $16.045 | $15.68 | $15.92 | 1.71M |
| Oct 27, 2026 | $15.56 | $16.175 | $15.475 | $16.02 | 2.23M |
| Oct 26, 2026 | $16.05 | $16.21 | $15.745 | $15.82 | 1.5M |
| Oct 23, 2026 | $16.22 | $16.33 | $15.88 | $15.96 | 1.56M |
| Oct 22, 2026 | $15.99 | $16.45 | $15.895 | $16.37 | 1.78M |
| Oct 21, 2026 | $16.01 | $16.125 | $15.58 | $15.91 | 2.36M |
| Oct 20, 2026 | $16.34 | $16.6799 | $16.08 | $16.17 | 1.77M |
| Oct 19, 2026 | $16.59 | $16.79 | $16.025 | $16.09 | 2.89M |
| Oct 16, 2026 | $16.54 | $16.68 | $16.26 | $16.63 | 2.44M |
| Oct 15, 2026 | $16.16 | $16.655 | $16.08 | $16.48 | 3.31M |
| Oct 14, 2026 | $15.29 | $16.17 | $15.13 | $15.95 | 4.64M |
| Oct 13, 2026 | $15.19 | $15.73 | $15.19 | $15.37 | 1.76M |
| Oct 12, 2026 | $14.90 | $15.515 | $14.855 | $15.45 | 1.84M |
| Oct 9, 2026 | $14.24 | $15.52 | $14.24 | $15.06 | 4.4M |
| Oct 8, 2026 | $14.45 | $14.561 | $14.10 | $14.50 | 2.88M |
| Oct 7, 2026 | $14.00 | $14.615 | $14.00 | $14.55 | 1.91M |
| Oct 6, 2026 | $14.57 | $14.63 | $13.91 | $14.00 | 2.04M |
| Oct 5, 2026 | $14.20 | $14.575 | $14.02 | $14.44 | 1.88M |
| Oct 2, 2026 | $14.18 | $14.80 | $14.12 | $14.26 | 2.17M |
The latest Smart Investors Daily articles mentioning PRGO.
Company
Market Activity
Research & News
PRGO research
Company profile and research snapshot.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 27, 2026 | Canaccord Genuity | Buy | — |
| Dec 15, 2025 | JP Morgan | Neutral | — |
| Nov 6, 2025 | Canaccord Genuity | Buy | — |
| Nov 6, 2025 | JP Morgan | Neutral | — |
| Oct 27, 2025 | Jefferies | Hold | — |
No generated briefing is available yet.
Benzinga · Oct 23, 2026
Analysts highlight high-yield healthcare stocks Perrigo (7.09%), Pfizer (5.65%) and CVS Health (2.82%), with updated ratings and news.
Yahoo · Oct 21, 2026
Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that it plans to release its third quarter 2026 financial results on Wednesday, November 4, 2026. The company will hold a conference call beginning at 8:30 a.m. (ET) hosted by Interim President and CEO Albert Manzone and CFO Eduardo Bezerra.
Yahoo · Oct 21, 2026
Abbott (ABT) delivered earnings and revenue surprises of -0.70% and +0.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 16, 2026
Perrigo shares have rebounded over the past month, and after a long stretch of weaker long term returns the key issue now is whether the current price can be explained by the revenue the business generates. For anyone watching the recent move, the question is how that sales base stacks up against what the market is now willing to pay. Over 5 years the stock has fallen 54.7%, which puts the focus squarely on whether today's valuation is better supported by its sales than it has been in the...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRGO.
